

1 **The PAZ domain of *Aedes aegypti* Dicer 2 is critical for accurate and high-fidelity size**  
2 **determination of virus-derived small interfering RNAs.**

3

4 Melinda Reuter<sup>1,2,3,4#</sup>, Rhys H. Parry<sup>5#</sup>, Melanie McFarlane<sup>1</sup>, Rommel J. Gestuveo<sup>6</sup>, Rozeena  
5 Arif<sup>1</sup>, Alexander A. Khromykh<sup>5,7</sup>, Benjamin Brennan<sup>1</sup>, Margus Varjak<sup>8</sup>, Alfredo Castello<sup>1</sup>, Lars  
6 Redecke<sup>9,10</sup>, Esther Schnettler<sup>2,3,4\*</sup>, Alain Kohl<sup>1,11\*</sup>

7

8 <sup>1</sup>MRC-University of Glasgow Centre for Virus Research, Glasgow, UK; <sup>2</sup>Bernhard-Nocht-  
9 Institute for Tropical Medicine, Hamburg, Germany; <sup>3</sup>German Centre for Infection Research  
10 (DZIF), Partner Site Hamburg-Luebeck-Borstel-Riems, Hamburg, Germany; <sup>4</sup>Faculty of  
11 Mathematics, Informatics and Natural Sciences, University Hamburg, Hamburg, Germany;  
12 <sup>5</sup>School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia,  
13 Australia; <sup>6</sup>Division of Biological Sciences, University of the Philippines Visayas, Miagao,  
14 Iloilo, Philippines; <sup>7</sup>Australian Infectious Diseases Research Centre, Global Virus Network  
15 Centre of Excellence, Brisbane, Queensland, Australia; <sup>8</sup>Institute of Technology, University  
16 of Tartu, Estonia; <sup>9</sup>University of Lübeck, Institute of Biochemistry, Lübeck, Germany;  
17 <sup>10</sup>Deutsches Elektronen Synchrotron (DESY), Photon Science, Hamburg, Germany;  
18 <sup>11</sup>Centre for Neglected Tropical Diseases, Departments of Tropical Disease Biology and  
19 Vector Biology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK

20

21 #These authors contributed equally to this manuscript.

22 \*Correspondence: [schnettler@bnitm.de](mailto:schnettler@bnitm.de) and [alain.kohl@lstmed.ac.uk](mailto:alain.kohl@lstmed.ac.uk)

23

24 Short title: Analysis of the *Aedes aegypti* Dicer 2 PAZ domain

25 Keywords: RNA interference; small RNA; Dcr2; arbovirus; mosquito cell; host response.

26

27

28 **ABSTRACT**

29 The exogenous siRNA (exo-siRNA) pathway is a critical RNA interference response involved  
30 in controlling arbovirus replication in mosquito cells. It is initiated by the detection of viral  
31 long double-stranded RNA (dsRNA) by the RNase III enzyme Dicer 2 (Dcr2), which is  
32 processed into predominantly 21 nucleotide (nt) virus-derived small interfering RNAs, or  
33 vsRNAs that are taken up by the Argonaute 2 (Ago2) protein to target viral single-stranded  
34 RNAs. The detailed understanding of Dicer structure, function and domains owes much to  
35 studies outside the context of viral infection and studies in model organisms, and as such  
36 how Dcr2 domains contribute to detecting viral dsRNA to mount antiviral responses in  
37 infected mosquito cells remains less well understood. Here, we used a Dcr2 reconstitution  
38 system in *Aedes aegypti* derived Dcr2 KO cells to assess the contribution of the PAZ domain  
39 to induction of the exo-siRNA pathway following infection with Semliki Forest virus (SFV;  
40 *Togaviridae, Alphavirus*). Amino acids critical for PAZ activity were identified, and loss of  
41 PAZ function affected the production of 21 nt vsRNAs -with enrichment of 22 nt SFV-derived  
42 small RNAs observed- and silencing activity. This study establishes PAZ domain's functional  
43 contribution to Dcr2 processing of viral dsRNA to 21 nt vsRNAs.

44

45 **INTRODUCTION**

46 The emergence and re-emergence of arboviruses pose a continuing threat to human and  
47 animal health, with mosquito-transmitted pathogens such as dengue virus (DENV;  
48 *Flaviviridae, Flavivirus*), Zika virus (ZIKV; *Flaviviridae, Flavivirus*) and chikungunya virus  
49 (CHIKV; *Togaviridae, Alphavirus*) as prominent examples of the threats posed (Zaid et al.  
50 2021; Halstead 2019; Weaver et al. 2018; Weaver and Reisen 2010; Huang et al. 2019;  
51 Pierson and Diamond 2020). The mosquito *Aedes aegypti* is an important vector for the  
52 transmission of many human-infecting arboviruses, including DENV, ZIKV and CHIKV. It is  
53 found across many areas of the tropics and subtropics where it is well adapted to the human  
54 environment, preferentially taking bloodmeals from human hosts which can result in  
55 arbovirus transmission. Prevention of transmission frequently relies on chemical control

56 measures that target vectors, though novel approaches such as *Wolbachia* endosymbionts  
57 and gene drive-based approaches are promising (Achee et al. 2019; Facchinelli et al. 2023;  
58 Carvalho and Moreira 2017; Brady and Hay 2020; Caragata et al. 2021; Wang et al. 2021,  
59 2022).

60 Arboviruses actively replicate in their vectors, which results in the induction of immune  
61 responses. Understanding these is relevant for a better comprehension of vector processes  
62 that impact arbovirus transmission and thus targets for intervention (Alonso-Palomares et al.  
63 2018; Lambrechts and Saleh 2019). Among host responses that control arbovirus replication  
64 in vectors, the RNA interference response -specifically the exogenous siRNA (exo-siRNA)  
65 pathway- plays a critical role. Much of our current understanding of this pathway comes from  
66 studies in *Drosophila melanogaster*, including *in vitro* studies, with critical components and  
67 mechanisms also conserved in mosquitoes thus, proving the importance of the exo-siRNA  
68 pathway across insects. It is initiated following targeting of viral replication induced long  
69 double-stranded RNA (dsRNA) by the RNase III enzyme Dicer 2 (Dcr2), which cleaves the  
70 dsRNA into virus-derived small interfering RNAs (vsiRNAs). In mosquitoes and *D.*  
71 *melanogaster*, each vsiRNA strand is predominantly 21 nucleotides (nt) in length, with a 19  
72 nt overlap and 2 nt overhangs at the 3' end. In the next step, 21 nt vsiRNAs are taken up by  
73 Argonaute 2 (Ago2). Ago2 is part of the RNA-induced silencing complex (RISC) and retains  
74 one strand of the siRNA to target and degrade complementary viral RNAs (Blair and Olson  
75 2015; Tikhe and Dimopoulos 2021; Olson and Blair 2015; Bronkhorst and van Rij 2014;  
76 Swevers et al. 2018; Prince et al. 2023; Leggewie and Schnettler 2018; Samuel et al. 2018).  
77 Indeed, absence of Dcr2 in mosquito cell lines resulted in the loss of 21 nt vsiRNAs and  
78 impaired antiviral responses (Brackney et al. 2010; Gestuveo et al. 2022; Scott et al. 2010;  
79 Varjak et al. 2017), while *Ae. aegypti* mosquitoes without functional Dcr2 develop disease  
80 phenotypes, increased replication and dissemination following arbovirus infection (Merkling  
81 et al. 2023; Samuel et al. 2023). These data show the importance of Dcr2 as an initiator of  
82 the exo-siRNA pathway, but other functional aspects of this effector protein are less  
83 understood especially in the context of viral infection and targeting of viral derived dsRNA.

84 The domain structure of *Ae. aegypti* Dcr2 (Aaeg Dcr2) is similar to that of *D. melanogaster*  
85 Dcr (Dm Dcr2), with helicase-DUF-PAZ-RNase 3A-RNase 3B-dsRBD from N to C terminus  
86 of the protein (Fig. 1), though other functional domains are present in the protein, too (Paturi  
87 and Deshmukh 2021). Structural studies have revealed that Dicer proteins generally have an  
88 L shape in which these different domains are arranged (Paturi and Deshmukh 2021; Zapletal  
89 et al. 2023; Ciechanowska et al. 2021). Analyses of Dm Dcr2 have confirmed this shape  
90 (Yamaguchi et al. 2022; Sinha et al. 2018; Su et al. 2022) , which was also predicted for  
91 Aaeg Dcr2 using AlphaFold (Gestuveo et al. 2022). The bottom (or base) module of the L-  
92 shaped Dcr2 structure contains the helicase domain; the core comprises RNase 3A/B and  
93 dsRBD domains, and the cap module the PAZ (Piwi/Ago/Zwille) domain. Biochemical and  
94 structural studies have investigated the dsRNA binding properties of Dm Dcr2 domains, with  
95 the PAZ domain preferably binding dsRNA termini with 3' overhangs (Sinha et al. 2018). The  
96 structural arrangements of the 3' nt overhang binding pocket in the PAZ domain and 5'  
97 monophosphate in the adjacent Platform domain have been investigated in detail.  
98 Importantly, interactions of dsRNA with PAZ and Platform via 3' 2 nt overhang and 5'  
99 monophosphate of the dsRNA allows positioning and spacing of the dsRNA for precise  
100 dicing activity and siRNA length (Su et al. 2022; Yamaguchi et al. 2022). These structural  
101 data consolidate a previous study on the importance of binding of the 5' monophosphate in  
102 dsRNA for length fidelity in 21 nt siRNA production from long dsRNA- though not efficiency  
103 of small RNA production *per se*; and mutagenesis analysis of the Dm Dcr2 PAZ domain also  
104 demonstrated the critical role of 21 nt siRNAs in silencing an inverted repeat transgene in  
105 the fly model (Kandasamy and Fukunaga 2016). Interestingly, the presence of 5'  
106 monophosphate and two specific arginine residues in Dm Dcr2 PAZ were found to be critical  
107 for cleavage of short dsRNA (Cenik et al. 2011; Fukunaga et al. 2014), though not longer  
108 ones where (as stated above) accurate length determination of siRNAs is the critical  
109 contribution of 5' monophosphate binding to the dicing process.  
110 A limitation of studies on Dm Dcr2 PAZ domain is their reliance on *in vitro* studies with  
111 dsRNA substrates or endogenous small RNAs, while the role of this domain in antiviral

112 responses during infection when targeting viral derived dsRNA in the cell is, to our  
113 knowledge, still unclear. The importance of the Dcr2 helicase domain in antiviral responses  
114 has been previously shown (Gestuveo et al. 2022; Marques et al. 2013; Donelick et al.  
115 2020), there remains a critical gap because the nature of the viral dsRNA substrate is  
116 unknown- does Dcr2 detect long, short, or different types of dsRNA in infected cells, and  
117 how does recognition occur? Here we aimed to expand our previous studies on the role of  
118 Dcr2 domains in mosquito cell antiviral responses by investigating the role of the Aaeg Dcr2  
119 PAZ domain in mosquito antiviral vsiRNA generation and its requirement for efficient antiviral  
120 responses. For this, we used the previously described Aaeg Dcr2 activity reconstitution  
121 system in *Ae. aegypti* derived Dcr2 KO cells, with which we demonstrated the importance of  
122 the helicase and RNase domains and that 21 nt vsiRNAs are generally produced by a  
123 processive production mechanism from viral dsRNA (Gestuveo et al. 2022). To understand  
124 the contribution of the PAZ domain to the antiviral activity of Aaeg Dcr2, we identified  
125 conserved amino acids in Aaeg Dcr2 PAZ domain which were mutated to assess their  
126 impact on dsRNA processing activity. Mutations abrogated antiviral activity against a positive  
127 sense RNA virus, Semliki Forest virus (SFV), a member of the *Togaviridae* family, genus  
128 *Alphavirus*. PAZ function inactivating mutations resulted in a loss of 21 nt vsiRNA  
129 generation, and enrichment of 22 nt SFV-derived small RNAs. These findings indicate that  
130 PAZ domain functionality is critical for determination of the usually predominant vsiRNA  
131 length of 21 nt, but mutations did not affect processive cleavage of viral dsRNA as such.

132

## 133 **RESULTS**

### 134 **Identification of amino acids in Aaeg Dcr2 PAZ domain required for antiviral activity.**

135 Analysis of Aaeg Dcr2 sequence (InterProScan, Geneious) indicated that the PAZ domain  
136 was located from positions N824 to G941 (Fig. 1A). This was in line with NCBI domain  
137 analysis, which also located the PAZ domain between amino acids 824-941. Next, Dcr2 PAZ  
138 domain sequences of *Ae. aegypti* (including recently available sequences, see (Gestuveo et  
139 al. 2022)), *Ae. albopictus*, *D. melanogaster* as well as *Anopheles* and *Culex* spec. were

140 aligned to identify highly conserved amino acids in the PAZ domain and thus with potential  
141 functional activities. Several positions, as shown in Fig. 1B, were either fully conserved  
142 between at least *Ae. aegypti*, *Ae. albopictus*, and *D. melanogaster* Dcr2 PAZ domains  
143 (amino acids D829, N872, V880, V883, Y909, V923) OR across mosquitoes (amino acid  
144 L930) and chosen for mutagenesis in different combinations, which we assumed would give  
145 the best chance of success to disrupt PAZ domain functionality. For completeness,  
146 corresponding amino acid positions in Dm Dcr2 are indicated in Fig. 2A. Using NCBI domain  
147 analysis, the PAZ domain of Dm Dcr2 (1722 amino acids in length) was shown as located  
148 from amino acids 843-1004.

149

150 Alphafold was used to determine the location/structure of these conserved amino acids  
151 within the structure of the *Aeeg* Dcr2 PAZ domain, which appeared mainly located (with the  
152 exception of L930) around its core (Supplemental Fig. S1) when compared to Dm Dcr2  
153 (Yamaguchi et al. 2022), suggesting structural and/ or functional importance.

154 Combinatorial mutagenesis was carried out as described for mutants M1-4, with conserved  
155 amino acids replaced in the combinations shown as indicated with the aim of achieving  
156 disruption PAZ domain function with a high degree of certainty (Fig. 2A). PAZ domain  
157 mutant M1-M4 and WT Dcr2 expression in AF319 Dcr2 KO cells transfected with the  
158 corresponding expression constructs was assessed by western blot, showing that all  
159 proteins were expressed (Fig. 2B, Supplemental Fig. S2).

160

161 Next, we assessed the functionality of the *Aeeg* Dcr2 mutants for their silencing ability and  
162 antiviral activity. WT Dcr2 displayed antiviral activity against SFV-FFLuc in this transfection-  
163 based assay (Fig. 3), as previously demonstrated (Gestuveo et al. 2022). M1-M4 Dcr2  
164 mutants lost SFV-FFLuc antiviral activity, compared to WT Dcr2. Similarly, the functional  
165 silencing abilities of the mutant Dcr2 were investigated in a reporter plasmid-based assay,  
166 where exogenous dsRNA is provided to induce the exo-siRNA pathway against a reporter  
167 gene (Gestuveo et al. 2022). Here, M1-M4 Dcr2 mutants only retained residual (although

168 significant compared to control) ability to silence the reporter gene. This indicated that the  
169 mutation combinations in M1-M4 all affected Dcr2 PAZ domain functionality, and thus Dcr2's  
170 ability as an effector in the exo-siRNA pathway.

171

172 **Aaeg Dcr2 PAZ domain loss of function mutations: effects on 21 nt vsiRNA**  
173 **production.**

174 The impact of Aaeg Dcr2 PAZ domain mutations on vsiRNA production was investigated  
175 utilising high throughput small RNA sequencing from AF319 cells transiently expressing  
176 Dcr2 PAZ domain mutants or WT Dcr2 and infected with SFV. Raw populations of small  
177 RNA read lengths prototypical of miRNAs (22 nt), siRNAs (21 nt) and piRNAs (24-30 nt)  
178 (Supplemental Fig. S3) were observed in all cells. Small RNA profiles from Dcr2 PAZ  
179 domain mutants M1-4 and the eGFP control demonstrated a bias towards a read length of  
180 22 nt rather than 21 nt observed in the WT Dcr2 expressing cells. Read mapping profiles of  
181 SFV-derived small RNAs indicated that WT Dcr2 efficiently mediated the production of SFV-  
182 derived 21 vsiRNAs (Fig. 4A), which are (as expected, see (Gestuveo et al. 2022)) the  
183 predominant length in the 18-22 nt size range and aligned along the length of the SFV  
184 genome and antigenome. Almost no such vsiRNAs were detected in the eGFP control.  
185 Importantly, M1-M4 Dcr2 mutants showed reduced production of 21 nt vsiRNAs (though  
186 those remaining align along the length of SFV4 genome and antigenome) and a more even  
187 distribution of read numbers across the 20-22 nt small RNA size range, compared to WT  
188 Dcr2, was observed. This indicates that Dcr2 PAZ domain mutants M1-M4 have lost the  
189 ability to precisely measure siRNA length and consequently do not predominantly produce  
190 21 nt vsiRNAs; but have retained the ability to process viral dsRNA into small RNAs.  
191 Crucially we examined absolute magnitudes of SFV-derived small RNAs in the sizes of 20 nt  
192 and 22 nt and observed a clear enrichment for 22 nt, ranging from 2.18-fold (Dcr 2 PAZ  
193 domain mutant M3) to 3.02-fold (Dcr2 PAZ domain mutant M4) (Fig. 4B). For the 20 nt size,  
194 we found modest or no significant change (0.91-1.45fold) consistent with previous results  
195 (Kandasamy and Fukunaga 2016). Critically, AlphaFold 3 based modelling of Aaeg Dcr2

196 PAZ domain interactions with dsRNA suggested that mutations did not abrogate the ability to  
197 bind dsRNA (Supplemental Fig. S4). This consolidates the idea that conserved amino acid  
198 are required for keeping dsRNA in a precise position for accurate cleavage to occur.

199

200 **Virus-derived small RNAs retain a 2 nt overhang cleavage pattern independently of**  
201 **Aaeg Dcr2 PAZ domain functionality.**

202 The predominant 21 nt vsiRNAs produced by Dcr2 cleavage that are commonly observed  
203 following arbovirus infection of mosquito cells are generated as duplexes. Assuming that  
204 mechanisms observed for *D. melanogaster* also apply in mosquitoes, they consist of two 21  
205 nt strands that overlap by 19 nt with a 2 nt overhang at each 3' end. To investigate if and  
206 how dsRNA cleavage patterns were affected by the PAZ domain for generating virus-derived  
207 small RNAs, we analysed strand overlapping small RNA patterns (Fig. 5A, heat maps that  
208 show mean overlap probability z-scores of SFV-derived small RNAs 18-30 nt; Fig. 5B,  
209 showing number of overlapping pairs per million mapped reads of 19-23 nt SFV-derived  
210 small RNAs). For WT Dcr2, but also Dcr2 PAZ domain mutants M1-M4, all virus derived  
211 small RNAs in the range of 18-23 nt all showed a clear pattern, with strand complementarity  
212 significantly enhanced for overlaps that result in 2 nt overhangs. For example, 21 nt vsiRNAs  
213 overlapped with complementary sequences also by 19 nt (thus confirming observations in *D.*  
214 *melanogaster*); virus-derived small RNAs that are 20 nt in length overlapped with sequences  
215 that are 18 nt in length etc. This showed that PAZ domain mutations affected Aaeg Dcr2's  
216 ability to produce the usually predominant 21 vsiRNA over other lengths but did not affect  
217 the cleavage mechanism itself. We did however note a higher frequency of precise 2 nt  
218 overhangs for virus-derived small RNAs in AF319 expressing M1-M4 Dcr2 mutants  
219 compared to WT Dcr2. Indeed, further analysis noted a marked Z score drop for example for  
220 19 nt overlap (in 21 nt vsiRNA) and +2 nt overhangs for WT Dcr2 compared to Dcr2 PAZ  
221 domain mutants M1-M4 (Supplemental Fig. S5, left panel). Interestingly, when we  
222 reanalysed 21 nt vsiRNA data previously published from SFV infection of the Ago2 KO cell  
223 line AF525, compared to parental AF5 cells (Scherer et al. 2021), we also observed higher



224 frequencies of virus-derived small RNA duplexes with +2 nt overhangs (Supplemental Fig.  
225 S5, right panel). This leaves the possibility that failure to efficiently transfer or to Ago2, or  
226 fully process small RNA (and failure to degrade passenger strands) contributes to the  
227 increased presence of intact virus-derived small RNAs duplexes that are detected in this  
228 overlap analysis.

229 Production of virus-derived PIWI-interacting small RNAs (vpiRNAs), which are generally  
230 longer (24-30 nt) with a 10 nt overlap of the sense and antisense piRNAs as a result of the  
231 so-called ping-pong amplification mechanism in a Dcr2 independent manner (Varjak et al.  
232 2018), was detected across all conditions.

233

#### 234 **Loss of Aaeg Dcr2 PAZ domain functionality changes the position and magnitude of** 235 **vsiRNA cleavage.**

236 We have previously shown that Aaeg Dcr2 produces a diverse but largely consistent pool of  
237 21 nt vsiRNAs following SFV infection; a characteristic lost in helicase domain mutants  
238 (Gestuevo et al. 2022). To assess the impact of PAZ domain mutations on virus-derived  
239 small RNA population, diversity and cleavage bias, we examined these through two different  
240 analyses. First we defined a position-based “harmony” metric which incorporates the strand  
241 bias and magnitude of the vsiRNAs and second, using a vsiRNA population approach where  
242 each unique siRNA was treated as an individual gene and examined differential vsiRNA  
243 expression between treatment groups. While visualization of virus-derived small RNA  
244 coverage, as demonstrated in Fig. 4, provides a reasonable indicator of the origin and  
245 magnitude of vsiRNAs, a more nuanced analysis of the consistency of Dcr2 cleavage over  
246 the SFV-derived dsRNA requires consideration of the position, magnitude and strandedness  
247 of 21 nt vsiRNAs. To develop a unified metric that encapsulates these attributes at each  
248 genomic position, we calculated the terminal 5' vsiRNA read depth at each position of the  
249 SFV genome and antigenome, and normalized the total depth to one. Subsequently, we  
250 computed the normalized differential coverage,  $d_i$ , as the difference between the normalised  
251 genome (positive-sense) and anti-genome (negative-sense) coverage proportions at each

252 position. The genome coverage proportion at position  $i$ ,  $G_i$ , is defined as the positive-sense  
 253 coverage at  $i$  divided by the total positive-sense coverage for all  $N$  positions. The anti-  
 254 genome coverage proportion,  $A_i$ , is similarly calculated as the negative-sense coverage at  $i$   
 255 normalized by the total negative-sense coverage. The formula for the normalized differential  
 256 coverage at each position  $i$  is given by:

$$257 \quad d_i = \frac{G_i}{\sum_{j=1}^N G_j} - \frac{A_i}{\sum_{j=1}^N A_j}$$

259 Through this measure, we obtained a ratio reflecting the balance of genome to antigenome  
 260 virus-derived small RNA coverage, which provides insight into the strand-specific cleavage  
 261 patterns of WT Dcr2 across the positions of the SFV genome. Using this metric, we  
 262 generated a series of scatter plots (Fig. 6A) to compare the  $d_i$  values for each position of the  
 263 SFV genome between WT Dcr2, negative control eGFP and the Dcr2 PAZ domain mutants  
 264 M1-M4. Importantly, if the  $d_i$  value was 0 for a position for the comparison between  
 265 treatments it was excluded from the analysis, keeping only non-zero  $d_i$  values for  
 266 downstream analysis. We utilized linear regression analysis to assess the relationship  
 267 between  $d_i$  values for all positions on the SFV genome from the WT Dcr2 and each mutant,  
 268 with the coefficient of determination ( $R^2$ ) reflecting the extent to which both treatments  
 269 shared related vsiRNA profile “harmony”. The regression analysis revealed varying degrees  
 270 of correlation, with the lowest correlation between the eGFP control treatments compared to  
 271 the WT Dcr2 ( $R^2=0.115$ ). This suggests very little positional cleavage harmony between the  
 272 WT Dcr2 and eGFP control, which is to be expected. Dcr2 PAZ domain mutants M1-M4  
 273 showed a more consistent pattern of Dcr2 cleavage to WT with  $R^2$  values between 0.39-  
 274 0.41. Finally, we compared  $d_i$  values for all 21 nt vsiRNA reads for all treatments and  
 275 between mutants and summarised the  $R^2$  values as a heat map (Figure 6B). The results  
 276 indicated that the PAZ domain mutants M1-M4 were more closely related to each other than  
 277 WT Dcr2 or eGFP control with  $R^2$  between 0.74-0.84, indicating that the introduced

278 mutations resulted in more harmonious cleavage patterns across the SFV genome but  
279 different from wild type.

280 In addition to analyzing positional cleavage patterns of 21 nt vsRNAs (Fig. 6A-B), we  
281 examined population-level patterns and diversity of SFV-derived small RNA populations for  
282 individual lengths of 20 nt, 21 nt, 22 nt, and 23 nt, as well as combined lengths of 20-23 nt  
283 by conducting a differential transcript abundance analysis using edgeR (Fig. 6C). Through  
284 the generation of a non-redundant list of unique small RNAs, we generated count tables and  
285 normalized for library size using the weighted trimmed mean of M-values (TMM) method.  
286 Through multi-dimensional scaling (MDS), plots we were able to visualize the relationships  
287 between the treatments. MDS plots are a form of dimensionality reduction; visually, the  
288 distances between points represent the dissimilarities or differences between the treatments.  
289 Specifically, these distances correspond to the leading log-fold changes between the  
290 treatments, which reflect the relative expression levels of vsRNAs across conditions. The  
291 MDS plots revealed varying degrees of similarity between the WT Dcr2 and Dcr2 PAZ  
292 domain mutant treatments across different virus-derived small RNA size classes. Notably,  
293 the 21 nt vsRNAs displayed distinct clustering patterns, indicating that specific mutations in  
294 the Dcr2 PAZ domain contribute to the altered distribution and abundance of these vsRNA  
295 species.

296

## 297 **DISCUSSION**

298 While the importance of the helicase domain has been demonstrated for both Dm and Aaeg  
299 Dcr2 antiviral responses (Gestuveo et al. 2022; Marques et al. 2013; Donelick et al. 2020),  
300 the relevance of the PAZ domain had not yet been investigated for Aaeg Dcr2 and  
301 processing of viral dsRNA in the context of arboviral replication in mosquito cells. Here, we  
302 identified conserved amino acids in Aaeg Dcr2 that inactivate PAZ domain function and  
303 antiviral activity. Critically, we observed that while inactivation did affect the production of 21  
304 nt vsRNA, it did not affect Aaeg Dcr2's virus-derived small RNA production in general but  
305 broadened the length of the produced SFV-derived small RNAs and led to an enrichment of

306 specifically 22 nt SFV-derived small RNAs, similar to previous mutational analysis of Dm  
307 Dcr2 PAZ domain (Kandasamy and Fukunaga 2016). Thus, key observations hold true for  
308 viral dsRNAs and Aaeg Dcr2. The specific functions that are affected by the mutations we  
309 set in Aaeg Dcr2 PAZ will require further investigation. However, structural modelling  
310 (Supplemental Fig. S1) suggests positioning mostly in the core of the PAZ domain and thus  
311 a role in the binding mechanism of the dsRNA termini. This is further confirmed by modelling  
312 Aaeg PAZ domain interactions with dsRNA (Supplemental Fig. S4). Suggesting that the  
313 location of dsRNA is not affected but most likely mutations destabilise binding and thus allow  
314 flexibility in the interaction, which in turn leads to variable small RNA lengths following  
315 cleavage and in particular enrichment of 22 nt SFV-derived small RNAs. We cannot of  
316 course fully exclude effects on dsRNA binding or impaired processing that may not be  
317 captured by our analysis. Importantly, the critical PAZ domain amino acids we described here  
318 in Aaeg Dcr2 are different from those previously identified in Dm Dcr2 (Kandasamy and  
319 Fukunaga 2016). Based on our and previous data that demonstrate the importance of the  
320 Dcr2 helicase domain in the exo-siRNA pathway, we propose that the helicase binds usually  
321 blunt-ended, long viral dsRNA and cleavage of these termini -which is likely to generate  
322 small RNAs of variable length- generates the first dsRNA terminus with 2 nt overhang and 5'  
323 monophosphate that will be used by the PAZ domain to anchor the dsRNA strand and allow  
324 Dcr2 to produce mostly, though not exclusively, 21 nt vsiRNAs, and phase variation from  
325 occasional unprecise binding that allows the production of a diverse pool of vsiRNAs from  
326 dsRNA, may therefore start from early cleavage events onwards. Importantly, the size of 21  
327 nt is critical and the most efficient siRNA length for silencing to target RNAs in the fly system  
328 (Kandasamy and Fukunaga 2016; Elbashir et al. 2001). It is intriguing to note that U is  
329 enriched in first position in libraries (Supplemental Fig. S3) compared to vsiRNAs where a  
330 bias towards C or G can be seen. Indeed this may be due to presence of host derived  
331 sequences eg. miRNAs that frequently have a U in the 5' first base position (Ghildiyal et al.  
332 2010; Mi et al. 2008; Warf et al. 2011). Indeed in *D. melanogaster*, it has been shown that  
333 siRNAs derived from siRNA pathway, for example following processing long dsRNA, give

334 rise to siRNAs with frequently C in position 1 which has been suggested to facilitate sorting  
335 into Ago2 (Ghildiyal et al. 2010) . A similar mechanism may be at play here in the production  
336 of vsiRNAs. Our data also suggest that maturation of vsiRNAs -by cleaving the passenger  
337 strand- is less efficient with Dcr2 PAZ domain mutants M1-M4. While the exact processes  
338 would need further investigations, the marked increases in duplexes (with +2 nt overhangs)  
339 similar to what is observed in Ago2 KO cells infected SFV where an accumulation of  
340 duplexes is seen (Scherer et al. 2021), might be due due for example to a failure of vsiRNAs  
341 to efficiently transfer into Ago2 via dysfunctional Dcr2 PAZ domain, or a processing issue.  
342 This requires further investigation, and there is a degree of “noisiness” in such assays that  
343 needs to be taken into account. Indeed, in our previous work (Gestuveo et al. 2022) for WT  
344 Dcr2, 19 nt overlaps with 2 nt overhangs for example in 21 nt vsiRNAs were easily observed  
345 than in this study. This may be due to technical issues, for example small RNA sequencing,  
346 transfection levels of Dcr2 expression plasmids etc. and to some extent production of stable  
347 Dcr2 expressing cell lines may remediate small differences for future work.

348

349 In summary, this study demonstrates the critical role of the Aaeg Dcr2 PAZ domain in the  
350 precise production of 21 nt vsiRNAs. Its critical contribution is in accurate vsiRNA length  
351 determination, which in turn is critical for the *Ae. aegypti* exo-siRNA to mount an antiviral  
352 response against SFV. Moreover, future work will determine how arboviruses of different  
353 families are targeted by Dcr2 and give us further insights into the nature of the viral dsRNA  
354 substrate.

355

## 356 **MATERIALS AND METHODS**

### 357 **Cells**

358 The Dcr2 knockout cell line Aag2-AF319 (subsequently abbreviated to AF319) used here is  
359 derived from *Ae. aegypti* Aag2-AF5 cells, a clone derived from the Aag2 cell line (provided  
360 by Kevin Maringer, The Pirbright Institute, UK) (Fredericks et al. 2019; Varjak et al. 2017).  
361 As previously described AF319 cells were cultured in Leibovitz's L-15 medium with

362 GlutaMax (Gibco) with 10% tryptose phosphate broth (TPB; Gibco), 10% fetal bovine serum  
363 (FBS; Gibco), and penicillin-streptomycin (pen-strep; 100 U/mL-100 µg/mL; Gibco) at 28 °C  
364 (Fredericks et al. 2019; Varjak et al. 2017). Cell lines are available as Aag2-AF319 (ECACC  
365 19022602) and Aag2-AF5 (ECACC 19022601) through Public Health England. Baby  
366 hamster kidney (BHK-21) cells are a commonly used cell line available at the MRC-  
367 University of Glasgow Centre for Virus Research; these cells were grown in Glasgow  
368 Minimum Essential Medium (GMEM; Gibco) supplemented with 10% TPB, 10% newborn  
369 calf serum (Gibco), and pen-strep at 37 °C with 5% CO<sub>2</sub>.

370

### 371 **Viruses**

372 Virus production from icDNA and plaque assay titrations were performed as previously  
373 described (Ulper et al. 2008; Varjak et al. 2017) to produce SFV4 (abbreviated to SFV;  
374 GenBank ID: KP699763) and SFV4(3H)-*FFLuc* (abbreviated to SFV-FFLuc; reporter virus  
375 expressing FFLuc).

376

### 377 **Plasmid generation**

378 Mutations in the PAZ domain of Aaeg Dcr2 (GenBank ID: AAW48725) were created by In-  
379 Fusion cloning of synthetically generated PAZ domain mutant fragments into the previously  
380 generated pPUB-myc-Dcr2 (Varjak et al. 2017) following the manufacturer's guidelines.  
381 Briefly, pPUB-myc-Dcr2 was linearised by PCR, removing the WT PAZ domain. Mutant PAZ  
382 domain fragments were PCR amplified using primers with extensions that were homologous  
383 to the linearised vector. In-Fusion cloning was then performed to create pPUB-myc-Dcr2  
384 constructs containing the various mutants. Mutations were based on multiple sequence  
385 alignment and identification of conserved amino acids in *Ae. aegypti*, *D. melanogaster* and  
386 *Ae. albopictus*.

387

388

389

## 390 **Virus infections**

391 For investigations of antiviral activity against SFV, AF319 cells were seeded at  $2 \times 10^5$   
392 cells/well in 24-well plates and transfected with 1  $\mu$ g pPub plasmid expressing WT or mutant  
393 Dcr2 or eGFP (as control) after 24 h using Dharmafect2 (Horizon Discovery) following the  
394 recommended protocol. At 24 hpt, the cells were infected with SFV-FFLuc (MOI=0.1) and  
395 lysed at 48 hpi using 1X Passive Lysis Buffer (PLB; Promega). FFLuc levels were measured  
396 using a Luciferase Assay System (Promega) according to the manufacturer's protocol in  
397 GloMax Multi-Detection System with Dual Injectors (Promega). For the production of  
398 samples for small RNA sequencing,  $2.5 \times 10^5$  cells/well AF319 cells were seeded in 8 wells  
399 of a 24 well plate, transfected as above after 24 h and infected with SFV (MOI=1) at 24 hpt  
400 for 48 h. For RNA extraction and follow up small RNA sequencing, cells from 7 wells were  
401 combined and lysed using TRIzol (Thermo Fisher Scientific) according to the manufacturer's  
402 guidelines, with glycogen as a carrier. The remaining well was lysed in LDS protein lysis  
403 buffer and used for confirmatory western blot analysis.

404

## 405 **dsRNA production**

406 FFLuc (dsFFLuc) and eGFP (dseGFP) were amplified using T7 RNA polymerase promoter-  
407 flanked primers (Varjak et al. 2017; McFarlane et al. 2020) and dsRNAs produced with  
408 MEGAscript RNAi kits (Thermo Fisher Scientific) by *in vitro* transcription as per  
409 manufacturer's guidelines. Following *in vitro* transcription, products were treated with  
410 DNaseI, and RNase A. dsRNA was purified by column purification.

411

## 412 **RNAi reporter assay**

413 RNAi reporter assays were performed as previously described (Varjak et al. 2017) to assess  
414 the silencing activities of mutant Dcr2 compared to WT Dcr2. For this,  $2 \times 10^5$  AF319  
415 cells/well were seeded in 24-well plates. After 24 h cells were co-transfected with 1  $\mu$ g  
416 pPub-based expression plasmid, 50 ng pGL3-PUB (Anderson et al. 2010) and 20 ng pPub-  
417 RLuc (Alexander et al. 2023) together with either 20 ng dsRNA targeting FFLuc (dsFFLuc)

418 or 20 ng dsRNA control (dseGFP) and lysed at 24 hpt in 1X PLB (Promega). To determine  
419 FFLuc/RLuc levels, dual luciferase assays were performed using a Dual-Luciferase Reporter  
420 Assay System (Promega) according to the manufacturer's protocol in a GloMax Multi-  
421 Detection System with Dual Injectors (Promega).

422

### 423 **Western blot analysis**

424 Cell lysis was performed in 1X Bolt sample reducing agent and 1X Bolt LDS sample buffer  
425 (Invitrogen). The lysate was separated using a 4-12% Bis-Tris Plus gel (Invitrogen). For  
426 transfer onto a nitrocellulose membrane, a Trans-Blot SD Semi-Dry Transfer Cell (BioRad)  
427 was used. Membranes were blocked for a minimum of 1 h using 5% (w/v) non-fat dry milk  
428 powder in PBS-Tween (PBS with 0.05% Tween 20, PBS-T) and then washed three times for  
429 10 min using PBS-T. As primary antibodies, mouse anti-myc tag antibody (1:2000, Abcam)  
430 and mouse anti- $\alpha$  tubulin antibody (1:2000; Sigma-Aldrich) in 5% (w/v) non-fat dry milk  
431 powder in PBS-T were used. After overnight incubation at 4 °C, membranes were again  
432 washed three times in PBS-T. This was followed by incubation of 1 h with goat anti-mouse  
433 DyeLight 800 (1:5000; Invitrogen) secondary antibody conjugated with a near fluorescent  
434 dye in 5% (w/v) non-fat dry milk powder in PBS-T. The membranes were again washed  
435 three times with PBS-T and a final wash with distilled water and analysed using an Odyssey  
436 CLx and Image Studio Lite v.5.2.5 (LI-COR Biosciences).

437

### 438 **Small RNA sequencing**

439 To investigate small RNA production, at least 1  $\mu$ g isolated total RNA per condition were  
440 sent for analysis. Small RNA sequencing was performed at BGI-Tech Solutions (DNBSeq,  
441 UMI small library, SE50), UMI being unique molecular identifiers. With a minimum of 10  
442 million clean reads, with final libraries resulting between 11-18 million reads (Supplemental  
443 Table S2).

444

445



## 446 **Small RNA analysis**

447 Using fastp (v0.23.2) (Chen et al. 2018), adapters and low-quality reads from basecalled fastq  
448 files were trimmed, retaining reads between 18-32 nt. The distribution of read sizes and first  
449 position bias was calculated using the script '1\_fastq\_histogram.sh' from the GitHub repository  
450 (rhparry/viral\_sRNA\_tools). Clean, trimmed reads were then mapped to the SFV genome  
451 (GenBank ID: KP699763) with Bowtie2 (v2.4.5) (Langmead and Salzberg 2012), using the  
452 sensitive mapping flag (`--sensitive`) as specified in the script '2\_mapping\_vrnas.sh'.  
453 Histograms of mapped read lengths and first base pair bias were generated using samtools  
454 (v1.16.1) and '3\_bam\_sRNA\_histogram.sh'. Output BAM files were filtered to include only the  
455 21 nt reads. Coverage statistics across the SFV genome were calculated using  
456 '4\_viral\_srna\_coverage.sh', which employs the bedtools genome coverage tool (v.2.27.1)  
457 (Quinlan and Hall 2010). For calculating the harmony metric, coverage at the 5' end (-5 flag)  
458 of each read was normalized over the whole genome. Normalised coverage files were  
459 processed with awk '{f[NR]=\$2;r[NR]=\$3;sumf+=\$2;sumr+=\$3} END {for (i=1;i<=NR;i++)  
460 {printf "%d %.6e\n", i, (f[i]/sumf)-(r[i]/sumr)}}}' to calculate  $d_i$  values for each position  $i$  of the  
461 SFV genome. Linear regression analyses for downstream analysis scatter plots of per position  
462  $d_i$  values of the SFV genome were analysed in GraphPad Prism (v10.0.2), and  $R^2$  values for  
463 all pairwise treatments were computed and presented as a heat map. Overlapping virus-  
464 derived small RNA pairs and overlap probabilities (z-score) were calculated iteratively from  
465 BAM files using the 'signature.py' small RNA signatures Python script, both single read lengths  
466 from 18-30 nt were calculated as per the following conditions (`--minquery 18 --maxquery 18 -`  
467 `--mintarget 18 --maxtarget 18 --minscope 1 --maxscope 18`), collective 18-30 nt read lengths  
468 were computed as follows (`--minquery 18 --maxquery 30 --mintarget 18 --maxtarget 30 --`  
469 `--minscope 1 --maxscope 30`) (Antoniewski 2014). To examine the diversity and populations of  
470 SFV-derived small RNA species, unique 20-23 nt SFV mapped reads were treated as discrete  
471 virus-derived small RNAs. Counts tables for all extracted SFV-derived small RNAs from  
472 extracted fasta files from individual libraries were converted, processed, and enumerated in  
473 bash (v.3.2). The dimensions of count tables for 20-23 nt virus-derived small RNA species (n

474 = 75710), 20 nt (n = 13430), 21 nt (n = 27592), 22 nt (n = 20536) and 23 nt (n = 14155)  
475 species. Differential gene expression analysis was performed using package edgeR (v.3.30.3)  
476 (Robinson et al. 2009) in R Studio (v.1.3.1073), with library size normalization using the  
477 weighted TMM method in calcNormFactors() and filtered for a minimum count of 10 with  
478 filterByExpr(). Relationships between samples were explored using an MDS plot of normalized  
479 count tables with plotMDS(top = 500) of all SFV-derived small RNA species.

480

### 481 **Protein structure predictions**

482 The WT sequence of *Aaeg* Dcr2 (GenBank ID: AAW48725) was used as a query for structure  
483 prediction. AlphaFold 2 algorithm (Jumper et al. 2021) was run in monomer mode using a local  
484 install of version 2.3.2 without any restrictions. The resulting models were examined and, in  
485 accordance with overall model quality predictions, summarised in mean pLDDT value with the  
486 highest quality model selected for further analysis. Structural analyses were performed in  
487 PyMOL Molecular Graphics System (version 4.5.0, Schrödinger, LLC). Domain positions were  
488 assigned and labelled by color based on GenBank sequence annotations, and residues  
489 mutated were highlighted.

490 *Ae. aegypti* Dcr2-dsRNA interactions were assessed using AlphaFold 3. The WT sequence of  
491 *Ae. aegypti* Dcr2 (GenBank ID: AAW48725) and derived mutant sequences (M1-M4) were  
492 modelled as interacting with dsRNA. The 53 bp dsRNA sequence was obtained from PDB ID:  
493 7W0E for *D. melanogaster* Dcr2 in the active dicing state (Su et al. 2022). Sequences for WT  
494 or M1-M4 *Ae. aegypti* Dcr2 and each mutant were fed into AlphaFold 3 webserver (Abramson  
495 et al. 2024) along with the dsRNA sequence to predict protein structures and their interaction  
496 with dsRNA. Molecular graphics and analysis of structures were performed using UCSF  
497 ChimeraX (Pettersen et al. 2021).

498

### 499 **Data analyses**

500 Virus-derived small RNA metrics, coverage and overlapping pairs analysis were visualized  
501 using GraphPad Prism (v10.0.2).

502 **DATA DEPOSITION**

503 Data underlying figures are available under <http://dx.doi.org/10.5525/gla.researchdata.1479>.  
504 Small RNA sequencing data generated for this study have been deposited in the NCBI  
505 Sequence Read Archive (SRA), available under accession number PRJNA1014654. Scripts  
506 utilized for small RNA analysis are available from the viral\_sRNA\_tools GitHub repository at:  
507 [https://github.com/rhparry/viral\\_sRNA\\_tools](https://github.com/rhparry/viral_sRNA_tools)

508

509 **SUPPLEMENTAL MATERIAL**

510 Supplemental material is available for this article.

511

512 **COMPETING INTEREST STATEMENT**

513 The authors declare no competing interests. The funders had no role in study design, data  
514 collection and analysis, decision to publish, or preparation of the manuscript.

515

516 **ACKNOWLEDGMENTS**

517 For the purpose of open access, the authors have applied a Creative Commons Attribution  
518 (CC BY) licence to any Author Accepted Manuscript version arising from this submission.

519 This study was supported by the UK Medical Research Council (MC\_UU\_12014/8,

520 MC\_UU\_00034/4) (A.K.) and (MR/R021562/1, MC\_UU\_00034/2) (A.C.); European

521 Research Council (ERC) Consolidator Grant 'vRNP-capture' N# 101001634 (A.C.);

522 German Centre for Infection Research (DZIF) (TTU 01.708) (E.S.); DFG (project

523 497659464) (M.R.); Wellcome Trust/Royal Society Sir Henry Dale Fellowship

524 (210462/Z/18/Z) (B.B.); Overseas Scholarship Scheme for PhD by Higher Education

525 Commission of Pakistan (R.A.).

526 Author contributions are recognised as follows. Conceptualization: M.R., R.P., M.M., R.J.G.,

527 A. C., M.V., L.R., E.S., A.K.; Methodology: M.M., M.R., R.P., R.A., R.J.G., L.R.; Formal

528 analysis: M.R., R.P., M.M., R.A., L.R.; Investigation: M.R., R.P., M.M., R. A., L.R.; Validation:

529 M.R., R.P., M.M., R.A., L.R.; Resources: A.A.K., B.B., A.C., L.R., E.S., A.K.; Writing -

530 Original Draft Preparation: M.R., R.P., M.M., R.J.G., R.A., A.C., L.R., E.S., A.K.; Writing -  
531 Review and Editing: M.R., R.P., M.M., R.J.G., R.A., A.A.K., B.B., M.V, A.C., L.R., E.S.,  
532 A.K.; Visualization: M.R., R.P, M.M., R.A., L.R.; Data Curation: M.R., R.P., M.M., E.S.,  
533 A.K.; Supervision: M.M., A.A.K., B.B., A.C., E.S., A.K.; Project Administration: M.M., E.S,  
534 A.K.; Funding Acquisition: R.A., B.B., A.C., E.S., A.K.  
535

536 **REFERENCES**

537

- 538 Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, Ronneberger O, Willmore L,  
539 Ballard AJ, Bambrick J, et al. 2024. Accurate structure prediction of biomolecular  
540 interactions with AlphaFold 3. *Nature*.
- 541 Achee NL, Grieco JP, Vatandoost H, Seixas G, Pinto J, Ching-Ng L, Martins AJ,  
542 Juntarajumnong W, Corbel V, Gouagna C, et al. 2019. Alternative strategies for  
543 mosquito-borne arbovirus control. *PLoS Negl Trop Dis* **13**: e0006822.  
544 <https://www.ncbi.nlm.nih.gov/pubmed/30605475>.
- 545 Alexander AJT, Salvemini M, Sreenu VB, Hughes J, Telleria EL, Ratinier M, Arnaud F, Volf  
546 P, Brennan B, Varjak M, et al. 2023. Characterisation of the antiviral RNA interference  
547 response to Toscana virus in sand fly cells. *PLoS Pathog* **19**: e1011283.  
548 <https://www.ncbi.nlm.nih.gov/pubmed/36996243>.
- 549 Alonso-Palomares LA, Moreno-Garcia M, Lanz-Mendoza H, Salazar MI. 2018. Molecular  
550 Basis for Arbovirus Transmission by *Aedes aegypti* Mosquitoes. *Intervirology* **61**: 255–  
551 264. <https://www.ncbi.nlm.nih.gov/pubmed/31082816>.
- 552 Anderson MA, Gross TL, Myles KM, Adelman ZN. 2010. Validation of novel promoter  
553 sequences derived from two endogenous ubiquitin genes in transgenic *Aedes aegypti*.  
554 *Insect Mol Biol* **19**: 441–449. <https://www.ncbi.nlm.nih.gov/pubmed/20456509>.
- 555 Antoniewski C. 2014. Computing siRNA and piRNA overlap signatures. *Methods Mol Biol*  
556 **1173**: 135–146. <https://www.ncbi.nlm.nih.gov/pubmed/24920366>.
- 557 Blair CD, Olson KE. 2015. The role of RNA interference (RNAi) in arbovirus-vector  
558 interactions. *Viruses* **7**: 820–843. <https://www.ncbi.nlm.nih.gov/pubmed/25690800>.
- 559 Brackney DE, Scott JC, Sagawa F, Woodward JE, Miller NA, Schilkey FD, Mudge J, Wilusz  
560 J, Olson KE, Blair CD, et al. 2010. C6/36 *Aedes albopictus* cells have a dysfunctional  
561 antiviral RNA interference response. *PLoS Negl Trop Dis* **4**: e856.  
562 <https://www.ncbi.nlm.nih.gov/pubmed/21049065>.
- 563 Brady OJ, Hay SI. 2020. The Global Expansion of Dengue: How *Aedes aegypti* Mosquitoes  
564 Enabled the First Pandemic Arbovirus. *Annu Rev Entomol* **65**: 191–208.  
565 <https://www.ncbi.nlm.nih.gov/pubmed/31594415>.
- 566 Bronkhorst AW, van Rij RP. 2014. The long and short of antiviral defense: small RNA-based  
567 immunity in insects. *Curr Opin Virol* **7**: 19–28.  
568 <https://www.ncbi.nlm.nih.gov/pubmed/24732439>.
- 569 Caragata EP, Dutra HLC, Sucupira PHF, Ferreira AGA, Moreira LA. 2021. Wolbachia as  
570 translational science: controlling mosquito-borne pathogens. *Trends Parasitol* **37**:  
571 1050–1067. <https://www.ncbi.nlm.nih.gov/pubmed/34303627>.
- 572 Carvalho FD, Moreira LA. 2017. Why is *Aedes aegypti* Linnaeus so Successful as a  
573 Species? *Neotrop Entomol* **46**: 243–255.  
574 <https://www.ncbi.nlm.nih.gov/pubmed/28401481>.
- 575 Cenik ES, Fukunaga R, Lu G, Dutcher R, Wang Y, Tanaka Hall TM, Zamore PD. 2011.  
576 Phosphate and R2D2 restrict the substrate specificity of Dicer-2, an ATP-driven  
577 ribonuclease. *Mol Cell* **42**: 172–184. <https://www.ncbi.nlm.nih.gov/pubmed/21419681>.
- 578 Chen S, Zhou Y, Chen Y, Gu J. 2018. fastp: an ultra-fast all-in-one FASTQ preprocessor.  
579 *Bioinformatics* **34**: i884–i890. <https://www.ncbi.nlm.nih.gov/pubmed/30423086>.
- 580 Ciechanowska K, Pokornowska M, Kurzynska-Kokorniak A. 2021. Genetic Insight into the  
581 Domain Structure and Functions of Dicer-Type Ribonucleases. *Int J Mol Sci* **22**.  
582 <https://www.ncbi.nlm.nih.gov/pubmed/33435485>.
- 583 Donelick HM, Talide L, Bellet M, Aruscavage J, Lauret E, Aguiar E, Marques JT, Meignin C,  
584 Bass BL. 2020. In vitro studies provide insight into effects of Dicer-2 helicase mutations  
585 in *Drosophila melanogaster*. *RNA*. <https://www.ncbi.nlm.nih.gov/pubmed/32843367>.
- 586 Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. 2001. Functional  
587 anatomy of siRNAs for mediating efficient RNAi in *Drosophila melanogaster* embryo  
588 lysate. *EMBO J* **20**: 6877–6888. <https://www.ncbi.nlm.nih.gov/pubmed/11726523>.

- 589 Facchinelli L, Badolo A, McCall PJ. 2023. Biology and Behaviour of *Aedes aegypti* in the  
590 Human Environment: Opportunities for Vector Control of Arbovirus Transmission.  
591 *Viruses* **15**. <https://www.ncbi.nlm.nih.gov/pubmed/36992346>.
- 592 Fredericks AC, Russell TA, Wallace LE, Davidson AD, Fernandez-Sesma A, Maringer K.  
593 2019. *Aedes aegypti* (Aag2)-derived clonal mosquito cell lines reveal the effects of pre-  
594 existing persistent infection with the insect-specific bunyavirus Phasi Charoen-like virus  
595 on arbovirus replication. *PLoS Negl Trop Dis* **13**: e0007346.  
596 <https://www.ncbi.nlm.nih.gov/pubmed/31693659>.
- 597 Fukunaga R, Colpan C, Han BW, Zamore PD. 2014. Inorganic phosphate blocks binding of  
598 pre-miRNA to Dicer-2 via its PAZ domain. *EMBO J* **33**: 371–384.  
599 <https://www.ncbi.nlm.nih.gov/pubmed/24488111>.
- 600 Gestuveo RJ, Parry R, Dickson LB, Lequime S, Sreenu VB, Arnold MJ, Khromykh AA,  
601 Schnettler E, Lambrechts L, Varjak M, et al. 2022. Mutational analysis of *Aedes aegypti*  
602 Dicer 2 provides insights into the biogenesis of antiviral exogenous small interfering  
603 RNAs. *PLoS Pathog* **18**: e1010202. <https://www.ncbi.nlm.nih.gov/pubmed/34990484>.
- 604 Ghildiyal M, Xu J, Seitz H, Weng Z, Zamore PD. 2010. Sorting of *Drosophila* small silencing  
605 RNAs partitions microRNA\* strands into the RNA interference pathway. *RNA* **16**: 43–  
606 56.
- 607 Halstead SB. 2019. Travelling arboviruses: A historical perspective. *Travel Med Infect Dis*  
608 **31**: 101471. <https://www.ncbi.nlm.nih.gov/pubmed/31472285>.
- 609 Huang YS, Higgs S, Vanlandingham DL. 2019. Emergence and re-emergence of mosquito-  
610 borne arboviruses. *Curr Opin Virol* **34**: 104–109.  
611 <https://www.ncbi.nlm.nih.gov/pubmed/30743191>.
- 612 Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K,  
613 Bates R, Zidek A, Potapenko A, et al. 2021. Highly accurate protein structure prediction  
614 with AlphaFold. *Nature* **596**: 583–589. <https://www.ncbi.nlm.nih.gov/pubmed/34265844>.
- 615 Kandasamy SK, Fukunaga R. 2016. Phosphate-binding pocket in Dicer-2 PAZ domain for  
616 high-fidelity siRNA production. *Proc Natl Acad Sci U S A* **113**: 14031–14036.  
617 <https://www.ncbi.nlm.nih.gov/pubmed/27872309>.
- 618 Lambrechts L, Saleh MC. 2019. Manipulating Mosquito Tolerance for Arbovirus Control. *Cell*  
619 *Host Microbe* **26**: 309–313. <https://www.ncbi.nlm.nih.gov/pubmed/31513769>.
- 620 Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. *Nat Methods*  
621 **9**: 357–359. <https://www.ncbi.nlm.nih.gov/pubmed/22388286>.
- 622 Leggewie M, Schnettler E. 2018. RNAi-mediated antiviral immunity in insects and their  
623 possible application. *Curr Opin Virol* **32**: 108–114.  
624 <https://www.ncbi.nlm.nih.gov/pubmed/30428425>.
- 625 Marques JT, Wang JP, Wang X, de Oliveira KP, Gao C, Aguiar ER, Jafari N, Carthew RW.  
626 2013. Functional specialization of the small interfering RNA pathway in response to  
627 virus infection. *PLoS Pathog* **9**: e1003579.  
628 <https://www.ncbi.nlm.nih.gov/pubmed/24009507>.
- 629 McFarlane M, Almire F, Kean J, Donald CL, McDonald A, Wee B, Laureti M, Varjak M, Terry  
630 S, Vazeille M, et al. 2020. The *Aedes aegypti* Domino Ortholog p400 Regulates  
631 Antiviral Exogenous Small Interfering RNA Pathway Activity and ago-2 Expression.  
632 *mSphere* **5**. <https://www.ncbi.nlm.nih.gov/pubmed/32269152>.
- 633 Merklings SH, Crist AB, Henrion-Lacritick A, Frangeul L, Couderc E, Gausson V, Blanc H,  
634 Bergman A, Baidaliuk A, Romoli O, et al. 2023. Multifaceted contributions of Dicer2 to  
635 arbovirus transmission by *Aedes aegypti*. *Cell Rep* **42**: 112977.  
636 <https://www.ncbi.nlm.nih.gov/pubmed/37573505>.
- 637 Mi S, Cai T, Hu Y, Chen Y, Hodges E, Ni F, Wu L, Li S, Zhou H, Long C, et al. 2008. Sorting  
638 of Small RNAs into Arabidopsis Argonaute Complexes Is Directed by the 5' Terminal  
639 Nucleotide. *Cell* **133**: 116–127.
- 640 Olson KE, Blair CD. 2015. Arbovirus-mosquito interactions: RNAi pathway. *Curr Opin Virol*  
641 **15**: 119–126. <https://www.ncbi.nlm.nih.gov/pubmed/26629932>.

- 642 Paturi S, Deshmukh M V. 2021. A Glimpse of “Dicer Biology” Through the Structural and  
643 Functional Perspective. *Front Mol Biosci* **8**: 643657.  
644 <https://www.ncbi.nlm.nih.gov/pubmed/34026825>.
- 645 Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, Morris JH, Ferrin TE.  
646 2021. <scp>UCSF ChimeraX</scp> : Structure visualization for researchers, educators,  
647 and developers. *Protein Science* **30**: 70–82.
- 648 Pierson TC, Diamond MS. 2020. The continued threat of emerging flaviviruses. *Nat*  
649 *Microbiol* **5**: 796–812. <https://www.ncbi.nlm.nih.gov/pubmed/32367055>.
- 650 Prince BC, Walsh E, Torres TZB, Ruckert C. 2023. Recognition of Arboviruses by the  
651 Mosquito Immune System. *Biomolecules* **13**.  
652 <https://www.ncbi.nlm.nih.gov/pubmed/37509194>.
- 653 Quinlan AR, Hall IM. 2010. BEDTools: a flexible suite of utilities for comparing genomic  
654 features. *Bioinformatics* **26**: 841–842. <https://www.ncbi.nlm.nih.gov/pubmed/20110278>.
- 655 Robinson MD, McCarthy DJ, Smyth GK. 2009. edgeR: a Bioconductor package for  
656 differential expression analysis of digital gene expression data. *Bioinformatics* **26**: 139–  
657 140. <https://doi.org/10.1093/bioinformatics/btp616>.
- 658 Samuel GH, Adelman ZN, Myles KM. 2018. Antiviral Immunity and Virus-Mediated  
659 Antagonism in Disease Vector Mosquitoes. *Trends Microbiol* **26**: 447–461.  
660 <https://www.ncbi.nlm.nih.gov/pubmed/29395729>.
- 661 Samuel GH, Pohlenz T, Dong Y, Coskun N, Adelman ZN, Dimopoulos G, Myles KM. 2023.  
662 RNA interference is essential to modulating the pathogenesis of mosquito-borne  
663 viruses in the yellow fever mosquito *Aedes aegypti*. *Proc Natl Acad Sci U S A* **120**:  
664 e2213701120. <https://www.ncbi.nlm.nih.gov/pubmed/36893279>.
- 665 Scherer C, Knowles J, Sreenu VB, Fredericks AC, Fuss J, Maringer K, Fernandez-Sesma A,  
666 Merits A, Varjak M, Kohl A, et al. 2021. An *Aedes aegypti*-derived Ago2 knockout cell  
667 line to investigate arbovirus infections. *Viruses* **13(6)**: 1066.
- 668 Scott JC, Brackney DE, Campbell CL, Bondu-Hawkins V, Hjelle B, Ebel GD, Olson KE, Blair  
669 CD. 2010. Comparison of dengue virus type 2-specific small RNAs from RNA  
670 interference-competent and -incompetent mosquito cells. *PLoS Negl Trop Dis* **4**: e848.  
671 <https://www.ncbi.nlm.nih.gov/pubmed/21049014>.
- 672 Sinha NK, Iwasa J, Shen PS, Bass BL. 2018. Dicer uses distinct modules for recognizing  
673 dsRNA termini. *Science (1979)* **359**: 329–334.  
674 <https://www.ncbi.nlm.nih.gov/pubmed/29269422>.
- 675 Su S, Wang J, Deng T, Yuan X, He J, Liu N, Li X, Huang Y, Wang HW, Ma J. 2022.  
676 Structural insights into dsRNA processing by *Drosophila* Dicer-2-Loqs-PD. *Nature* **607**:  
677 399–406. <https://www.ncbi.nlm.nih.gov/pubmed/35768513>.
- 678 Swevers L, Liu J, Smaghe G. 2018. Defense Mechanisms against Viral Infection in  
679 *Drosophila*: RNAi and Non-RNAi. *Viruses* **10**.  
680 <https://www.ncbi.nlm.nih.gov/pubmed/29723993>.
- 681 Tikhe C V, Dimopoulos G. 2021. Mosquito antiviral immune pathways. *Dev Comp Immunol*  
682 **116**: 103964. <https://www.ncbi.nlm.nih.gov/pubmed/33301792>.
- 683 Ulper L, Sarand I, Rausalu K, Merits A. 2008. Construction, properties, and potential  
684 application of infectious plasmids containing Semliki Forest virus full-length cDNA with  
685 an inserted intron. *J Virol Methods* **148**: 265–270.  
686 <https://www.ncbi.nlm.nih.gov/pubmed/18054090>.
- 687 Varjak M, Leggewie M, Schnettler E. 2018. The antiviral piRNA response in mosquitoes? *J*  
688 *Gen Virol* **99**: 1551–1562. <https://www.ncbi.nlm.nih.gov/pubmed/30372405>.
- 689 Varjak M, Maringer K, Watson M, Sreenu VB, Fredericks AC, Pondeville E, Donald CL,  
690 Sterk J, Kean J, Vazeille M, et al. 2017. *Aedes aegypti* Piwi4 Is a Noncanonical PIWI  
691 Protein Involved in Antiviral Responses. *mSphere* **2**.  
692 <https://www.ncbi.nlm.nih.gov/pubmed/28497119>.
- 693 Wang GH, Du J, Chu CY, Madhav M, Hughes GL, Champer J. 2022. Symbionts and gene  
694 drive: two strategies to combat vector-borne disease. *Trends Genet* **38**: 708–723.  
695 <https://www.ncbi.nlm.nih.gov/pubmed/35314082>.

- 696 Wang GH, Gamez S, Raban RR, Marshall JM, Alphey L, Li M, Rasgon JL, Akbari OS. 2021.  
 697 Combating mosquito-borne diseases using genetic control technologies. *Nat Commun*  
 698 **12**: 4388. <https://www.ncbi.nlm.nih.gov/pubmed/34282149>.  
 699 Warf MB, Johnson WE, Bass BL. 2011. Improved annotation of *C. elegans* microRNAs by  
 700 deep sequencing reveals structures associated with processing by Drosha and Dicer.  
 701 *RNA* **17**: 563–577.  
 702 Weaver SC, Charlier C, Vasilakis N, Lecuit M. 2018. Zika, Chikungunya, and Other  
 703 Emerging Vector-Borne Viral Diseases. *Annu Rev Med* **69**: 395–408.  
 704 <https://www.ncbi.nlm.nih.gov/pubmed/28846489>.  
 705 Weaver SC, Reisen WK. 2010. Present and future arboviral threats. *Antiviral Res* **85**: 328–  
 706 345. <https://www.ncbi.nlm.nih.gov/pubmed/19857523>.  
 707 Yamaguchi S, Naganuma M, Nishizawa T, Kusakizako T, Tomari Y, Nishimasu H, Nureki O.  
 708 2022. Structure of the Dicer-2-R2D2 heterodimer bound to a small RNA duplex. *Nature*  
 709 **607**: 393–398. <https://www.ncbi.nlm.nih.gov/pubmed/35768503>.  
 710 Zaid A, Burt FJ, Liu X, Poo YS, Zandi K, Suhrbier A, Weaver SC, Teixeira MM, Mahalingam  
 711 S. 2021. Arthritogenic alphaviruses: epidemiological and clinical perspective on  
 712 emerging arboviruses. *Lancet Infect Dis* **21**: e123–e133.  
 713 <https://www.ncbi.nlm.nih.gov/pubmed/33160445>.  
 714 Zapletal D, Kubicek K, Svoboda P, Stefl R. 2023. Dicer structure and function: conserved  
 715 and evolving features. *EMBO Rep* **24**: e57215.  
 716 <https://www.ncbi.nlm.nih.gov/pubmed/37310138>.  
 717

## 718 **Figure Legends**

719

720 **Figure 1. Domain features of Dcr2. (A)** Schematic representation of *D. melanogaster* and  
 721 *Ae. aegypti* Dcr2, including functional domains: Helicase domain, domain of unknown  
 722 function (DUF), PIWI-Argonaute-Zwille (PAZ) domain, RNase IIIA and IIIB domains, and  
 723 dsRNA binding domain (dsRBD); aa, amino acid **(B)** Multiple sequence alignment of insect  
 724 Dcr2 referring to Aaeg Dcr2 AAW48725, including the selected mutations of highly  
 725 conserved amino acids for potential PAZ domain loss of function. Accession numbers for  
 726 sequences used are indicated in Supplemental Table S1. Alignment was produced using  
 727 Benchling (<https://www.benchling.com/>).

728

729 **Figure 2. Mutation and expression of Aaeg Dcr2. (A)** Table showing produced Aaeg Dcr2  
 730 PAZ domain mutants M1-M4, the respective introduced loss-of-function mutations, as well as  
 731 corresponding amino acid residues in Dm Dcr2; aa, amino acid. **(B)** Assessment of (myc-  
 732 tagged) Aaeg Dcr2 expression by western blot analysis. AF319 cells were transfected with  
 733 either pPub plasmids expressing WT Dcr2 or Dcr2 PAZ domain mutants M1-M4, using pPub-



734 myc-eGFP as control. Anti-myc and anti- $\alpha$  tubulin (control) antibodies were used.  
735 Representative of three independent repeats (other repeats in Supplemental Fig. S2).

736

737 **Figure 3. Functional analysis of Aaeg Dcr2 PAZ domain mutants. (A)** Antiviral activity of  
738 Aaeg Dcr2. AF319 cells were transfected with expression plasmids encoding myc-tagged  
739 WT Dcr2 or Dcr2 PAZ domain mutants M1-M4 or eGFP (negative control). These cells were  
740 infected with SFV-FFLuc (MOI = 0.1) 24 hours post-transfection (hpt). FFLuc-levels were  
741 measured at 48 hours post-infection (hpi) and are shown as mean  $\pm$  SEM relative light units  
742 compared to eGFP control set to 1 from 3 independent repeats, performed in technical  
743 triplicate with \* indicating  $p < 0.05$  according to Student's t-test. **(B)** Silencing activity of  
744 mutant Aaeg Dcr2. AF319 cells were co-transfected with (i) myc-tagged pU6 plasmids  
745 expressing WT Dcr2 or Dcr2 PAZ domain mutants M1-M4 (with eGFP as control), (ii) FFLuc  
746 and RLuc (internal control) reporter plasmids and (iii) dsRNA targeting FFLuc (FFLuc  
747 dsRNA, blue) or eGFP (eGFP dsRNA; non-silencing control, grey). At 24 hpt, FFLuc and  
748 RLuc levels were measured and are shown as mean  $\pm$  SEM relative light units (FFLuc/RLuc)  
749 normalized to dseGFP from 3 independent repeats, performed in technical triplicate, with \* =  
750  $p < 0.05$ , \*\* =  $p < 0.01$ , \*\*\* =  $p < 0.001$  versus controls according to two-way ANOVA.

751

752 **Figure 4. Aaeg Dcr2 PAZ domain mutations affected 21 nt vsiRNA magnitude and**  
753 **length. (A)** Small RNA sequencing of AF319 cells, transiently expressing Dcr2 PAZ domain  
754 mutants M1-M4 or WT Dcr2, or eGFP (as negative control), and infected with SFV (MOI=1)  
755 at 48 hpi. Histogram of small RNA reads 18-30 nt in length, mapped to the SFV (SFV4  
756 GenBank ID: KP699763) genome (positive numbers) and antigenome (negative numbers)  
757 with colours indicating first base nucleotide prevalence per size, shown as mean % mapped  
758 reads (Y axis, percentage reads) from two independent experiments +/- SD. Mapping of  
759 SFV-derived 21 nt vsiRNAs, mapped along the SFV genome (magenta) or anti-genome  
760 (cyan) (Y axis, vsiRNA reads per million) +/- SD. **(B)** Fold change of magnitude of SFV-

761 derived small RNAs of lengths 20-22 nt of Dcr2 PAZ domain mutants M1-M4 compared to  
762 WT Dcr2.


763

764 **Figure 5. Aaeg Dcr2 PAZ domain mutations result in dysregulated vsiRNA duplex**  
765 **overlap lengths. (A)** Heat maps showing mean overlap probability z-scores of 18-30 nt  
766 SFV-derived small RNAs from AF319 transiently expressing Dcr2 PAZ domain mutant M1-  
767 M4 or WT Dcr2, or eGFP (control) from 2 independent repeats, as initially characterized in  
768 Fig 4. Differing lengths of vsiRNAs, analysed individually, are shown horizontally, and nt  
769 overlaps are listed vertically. The red arrow labelled Dcr2 indicates the expected 2 nt overlap  
770 from dsRNA cleavage with cells boxed in black. The black arrow labeled pp (ping-pong)  
771 shows the expected 10 nt overlap from potential ping-pong amplification in the piRNA  
772 pathway. **(B)** Number of overlapping pairs per million mapped reads of 19-23 nt virus-  
773 derived small RNAs from AF319 transiently expressing Dcr2 PAZ domain mutants M1-M4 or  
774 WT Dcr2, or eGFP (control) infected with SFV. Data are shown as the mean of 2  
775 independent repeats with the range of values.

776

777 **Figure 6. Mutations in the PAZ domain of Aaeg Dcr2 change the position and**  
778 **magnitude of cleavage over the SFV genome and virus-derived small RNA**  
779 **populations compared to WT Dcr2.** Samples from Fig 4 were analysed as follows. **(A)**  
780 Scatter plots showing normalized differential coverage ( $d_i$ ) for each position in the SFV  
781 genome. Each panel compares WT Dcr2 with no Dcr2, an eGFP expressing Dcr2 negative  
782 treatment, or Dcr2 PAZ domain mutants M1-M4. The linear regression line is depicted within  
783 each plot, with the  $R^2$  value indicating the fit of the model. The number of datapoints (n) with  
784  $d_i > 0$  over the SFV genome used for the calculation is shown on each graph. **(B)** Heatmap  
785 displaying pairwise  $R^2$  values from the linear regressions, comparing the similarity of  
786 differential coverage profile between treatments, as indicated. **(C)** Multidimensional scaling  
787 (MDS) plots representing the relationships between different size classes of vsiRNA reads  
788 from WT Dcr2, eGFP control and Dcr2 PAZ domain mutants M1-M4. Each plot corresponds


789 to a specific size class of SFV-derived small RNA: 20 nt, 21 nt, 22 nt, and 23 nt, as well as a  
790 combined plot of 20-23 nt. The axes represent the leading two log-fold change (logFC)  
791 dimensions and the percentage of variation indicated.  
792



**A****B**



<i>Ae. aegypti</i> Dcr2	— T H L D W K L —//— W Y K N N K —//— Y V V T M V H E —//— S Q A Y H L —//— L I E V K G —//— N R L N P G —
	▲ D829A N872A V880A/D V883A/D Y909A V923A/D L930A
<i>Ae. aegypti</i> Ben haplotype 3 Dcr2	— T H L D W E L —//— W Y K N N K —//— Y V V T M V H E —//— S Q A Y H L —//— L I E V K G —//— N R L N P G —
<i>Ae. aegypti</i> Ben haplotype 11 Dcr2	— T H I D W E L —//— W Y K N N K —//— Y V V T M V H E —//— S Q A Y H L —//— L I E V K G —//— N R L N P G —
<i>Ae. aegypti</i> Cay haplotype 1 Dcr2	— T H I D W K L —//— W Y K N N K —//— Y V V T M V H E —//— S Q A Y H L —//— L I E V K G —//— N R L N P G —
<i>Ae. aegypti</i> Cay haplotype 3 Dcr2	— T H I D W K L —//— W Y K N N K —//— Y V V T M V H E —//— S Q A Y H L —//— L I E V K G —//— N R L N P G —
<i>Ae. aegypti</i> Cay haplotype 4 Dcr2	— T H I D W K L —//— W Y K N N K —//— Y V V T M V H E —//— S Q A Y H L —//— L I E V K G —//— N R L N P G —
<i>Ae. aegypti</i> Guad haplotype 2 Dcr2	— T H I D W K L —//— W Y K N N K —//— Y V V T M V H E —//— S Q A Y H L —//— L I E V K G —//— N R L N P G —
<i>Ae. aegypti</i> Guad haplotype 3 Dcr2	— T H I D W K L —//— W Y K N N K —//— Y V V T M V H E —//— S Q A Y H L —//— L I E V K G —//— N R L N P G —
<i>Ae. aegypti</i> Guad haplotype 4 Dcr2	— T H I D W K L —//— W Y K N N K —//— Y V V T M V H E —//— S Q A Y H L —//— L I E V K G —//— N R L N P G —
<i>Ae. aegypti</i> KC haplotype 6 Dcr2	— T H I D W K L —//— W Y K N N K —//— Y V V T M V H E —//— S Q A Y H L —//— L I E V K G —//— N R L N P G —
<i>Ae. aegypti</i> Lope haplotype 7 Dcr2	— T H I D W E L —//— W Y K N N K —//— Y V V T M V H E —//— S Q A Y H L —//— L I E V K G —//— N R L N P G —
<i>Ae. aegypti</i> Lope haplotype 9 Dcr2	— T H I D W E L —//— W Y K N N K —//— Y V V T M V H E —//— S Q A Y H L —//— L I E V K G —//— N R L N P G —
<i>Ae. aegypti</i> Rat haplotype 1 Dcr2	— T H I D W K L —//— W Y K N N K —//— Y V V T M V H E —//— S Q A Y H L —//— L I E V K G —//— N R L N P G —
<i>Ae. aegypti</i> Rat haplotype 2 Dcr2	— T H I D W K L —//— W Y K N N K —//— Y V V T M V H E —//— S Q A Y H L —//— L I E V K G —//— N R L N P G —
<i>Ae. albopictus</i> Dcr2	— T H I D W E L —//— W Y K N N K —//— Y V V T M V H E —//— S E A Y H L —//— L I E V K G —//— N R L N P G —
<i>An. bellator</i> Dcr2	— T T I D W E L —//— W Y K N D P —//— Y V V L K V H E —//— T V Q H N Q —//— L I E V K G —//— N R L H P G —
<i>An. coustani</i> Dcr2	— E T I D W K L —//— W Y K H D A —//— Y V V V R V R E —//— A T E H H Q —//— L I E V K G —//— N R L H P G —
<i>An. gambiae</i> Dcr2	— Q S I D W E L —//— W Y K N D P —//— Y V V V R V R D —//— A Q E H H Q —//— L I E V K G —//— N R L H P G —
<i>An. ziemanni</i> Dcr2	— E T I D W K L —//— W Y K H D A —//— Y V V V R V R E —//— A T E H H Q —//— L I E V K G —//— N R L H P G —
<i>Cx. pipiens pallens</i> Dcr2	— R Q I D W Q V —//— W Y K T D R —//— F V V T A V H E —//— G T V Y G Q —//— L I E V K G —//— N R L S P G —
<i>Cx. pipiens pipiens</i> Dcr2	— V T V D W D F —//— W Y R N Q D —//— Y Y V A E I C Y —//— Y K K Y N I —//— L L E V D H —//— N F L T P R —
<i>Cx. quinquefasciatus</i> Dcr2	— R Q I D W Q V —//— W Y R T D R —//— Y V V T A V H E —//— G T V Y G Q —//— L I D V K G —//— N R L S P G —
<i>Cx. tarsalis</i> Dcr2	— R Q I D W Q V —//— W Y R T D R —//— Y V V T A V H E —//— G T V Y G Q —//— L I E V K G —//— N R L S P G —
<i>D. melanogaster</i> Dcr2	— K C F D W E L —//— W Y A N Y - —//— M L V T K V H R —//— M S K Y G N —//— M I E V R D —//— T F Y V H N —



**A**

Dcr2 mutant	Dcr2 mutations <i>Ae. aegypti</i>	Corresponding aa residues <i>D. melanogaster</i>
M1	V880A	V895
	V883A	V898
	Y909A	Y925
	V923A	V942
M2	V880D	V895
	V883D	V898
	Y909A	Y925
	V923D	V942
M3	D829A	D845
	N872A	N888
	V880A	V895
	V883A	V898
	Y909A	Y925
	V923A	V942
	L930A	Y949
M4	D829A	D845
	N872A	N888
	V880D	V895
	V883D	V898
	Y909A	Y925
	V923D	V942
	L930A	Y949



**B**

**A****B**

**A****B**

**A****WT****eGFP****M1****M2****M3****M4****B**







# RNA

A PUBLICATION OF THE RNA SOCIETY

## The PAZ domain of *Aedes aegypti* Dicer 2 is critical for accurate and high-fidelity size determination of virus-derived small interfering RNAs.

Melinda Reuter, Rhys H. Parry, Melanie McDonald, et al.

RNA published online February 13, 2025

---

**Supplemental Material** <http://rnajournal.cshlp.org/content/suppl/2025/02/13/rna.080149.124.DC1>

**P<P** Published online February 13, 2025 in advance of the print journal.

**Accepted Manuscript** Peer-reviewed and accepted for publication but not copyedited or typeset; accepted manuscript is likely to differ from the final, published version.

**Open Access** Freely available online through the *RNA* Open Access option.

**Creative Commons License** This article, published in *RNA*, is available under a Creative Commons License (Attribution 4.0 International), as described at <http://creativecommons.org/licenses/by/4.0/>.

**Email Alerting Service** Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).



---

To subscribe to *RNA* go to:  
<http://rnajournal.cshlp.org/subscriptions>